MyoKardia

MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
Type
Public
HQ
South San Francisco, US
Size (employees)
61 (est)
MyoKardia is headquartered in South San Francisco, US

Key People at MyoKardia

Charles Homcy

Charles Homcy

Interim CEO and Board Member

MyoKardia Office Locations

MyoKardia has an office in South San Francisco
South San Francisco, US (HQ)
333 Allerton Ave

MyoKardia Metrics

MyoKardia Financial Metrics

Net income (2016)

($13.2 m)

Market capitalization (28-Apr-2017)

$410 m

Closing share price (28-Apr-2017)

$12.9

Cash (31-Dec-2016)

$135.8 m
MyoKardia's current market capitalization is $410 m.
FY, 2015FY, 2016

R&D expense

$28.4 m$36.2 m

General and administrative expense

$9 m$16.3 m

Operating expense total

$37.4 m$52.5 m

EBIT

($23.2 m)($13.3 m)

Interest income

($47 k)$153 k

Net Income

($22.9 m)($13.2 m)
FY, 2015FY, 2016

Cash

$112.3 m$135.8 m

Inventories

$66.5 m$88.6 m

Current Assets

$113.5 m$186.3 m

PP&E

$2.7 m$2.8 m

Total Assets

$116.6 m$201.3 m

Accounts Payable

$190.8 m$259.5 m

Current Liabilities

$22 m$33 m

Additional Paid-in Capital

$158.6 m$223.2 m

Retained Earnings

($64.7 m)($77.8 m)

Total Equity

$93.9 m$145.4 m

Financial Leverage

1.2 x1.4 x
FY, 2015FY, 2016

Net Income

($22.9 m)($13.2 m)

Depreciation and Amortization

$965 k$1.1 m

Cash From Operating Activities

($32.1 m)($20.9 m)

Purchases of PP&E

($1.4 m)($1.1 m)

Cash From Investing Activities

($1.3 m)($17.1 m)

Cash From Financing Activities

$102 m$61.5 m

MyoKardia Market Value History

MyoKardia Online Presence

MyoKardia Company Life

You may also be interested in